Proteomics of post mortem brains in early‐ and late‐onset Alzheimer's disease: Unraveling differential Aβ effects and potential AD biomarkers
Alzheimer's & Dementia · 2026
DOI: 10.1002/alz.71662 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Evangelia Thanou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Neurobiology, Center for Neurogenomics & Cognitive Research, Neuroscience, Vrije Universiteit Amsterdam, Amsterd…. Hauptthemen laut MEDLINE: Alzheimer Disease, Proteomics, Amyloid beta-Peptides, Brain. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: EU Marie Curie ITN EuroNeurotrophin, Dutch Research Council (NWO), OPD-ZonMW via the MODEM consortium.
Themen: Demenz
Abstract (Originalsprache)
BACKGROUND Alzheimer's disease (AD) occurs primarily as late‑onset (LOAD) and less frequently as early‑onset (EOAD). Its defining pathologies are hyperphosphorylated tau tangles and amyloid beta (Aβ) plaques. METHODS We analyzed the proteomes of 115 post mortem temporal lobe samples by mass spectrometry and searched with a dedicated AD spectral library including tau post‑translational modifications and Aβ isoforms to examine global protein changes in LOAD and EOAD. RESULTS AD tissues showed mitochondrial and synaptic pathway downregulation and immune and small‑molecule metabolic process upregulation, with EOAD exhibiting larger fold changes. AD biomarkers were elevated, and two multi‑phosphorylated tau peptides (p‑tau231/p‐tau235 and p‐tau231/p‐tau235/p‐tau237) were detected predominantly in AD. Aβ was present in 45% of cognitively unimpaired elderly controls, with subtle proteome changes resembling an early stage of neurodegeneration. DISCUSSION EOAD appears more aggressive. Tau p‐tau231/p‐tau235 and p‐tau231/p‐tau235/p‐tau237 hold promise as novel AD biomarkers. Aβ’s detection in cognitively unimpaired elderly controls precedes clinical AD symptoms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Neurobiology, Center for Neurogenomics & Cognitive Research, Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.
- Department of Clinical Genetics, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, The Netherlands.
ORCID-Profile: Evangelia Thanou
Förderung
- EU Marie Curie ITN EuroNeurotrophin
- Dutch Research Council (NWO)
- OPD-ZonMW via the MODEM consortium
Zitieren
APA
Thanou, E., Ganz, A., Pita-Illobre, D., Koopmans, F., Hoozemans, J. J. M., Rozemuller, A., Holstege, H., Smit, A. B., & Li, K. W. (2026). Proteomics of post mortem brains in early‐ and late‐onset Alzheimer's disease: Unraveling differential Aβ effects and potential AD biomarkers. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71662
Vancouver
Thanou E, Ganz A, Pita-Illobre D, Koopmans F, Hoozemans JJM, Rozemuller A, et al. Proteomics of post mortem brains in early‐ and late‐onset Alzheimer's disease: Unraveling differential Aβ effects and potential AD biomarkers. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71662
BibTeX
@article{Thanou2026,
author = {Thanou, Evangelia and Ganz, Andrea and Pita-Illobre, Débora and Koopmans, Frank and Hoozemans, Jeroen J M and Rozemuller, Annemieke and Holstege, Henne and Smit, August B and Li, Ka Wan},
title = {Proteomics of post mortem brains in early‐ and late‐onset Alzheimer's disease: Unraveling differential Aβ effects and potential AD biomarkers},
journal = {Alzheimer's & Dementia},
year = {2026},
doi = {10.1002/alz.71662}
}
EUVIMED